Novo Nordisk (NVO) stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early.
The company put up roughly $12.1 billion in sales, easily beating forecasts for $10.89 billion, according to FactSet
That’s partially thanks to the new Wegovy pill, which has reached more than 5 million prescriptions in the U.S. since its launch. “Management believes… Related news Weight Loss Drug Stocks Slump. What Ozempic Maker Novo Nordisk Said. 7/31/2026 Novo Nordisk and Eli Lilly, the firms behind Ozemic, Wegovy and Zepbound, faced selling pressure on Friday. 7/31/2026 Novo Nordisk and Eli Lilly, the firms behind Ozemic, Wegovy